tbuckley/cabot-search huggingface dataset:
GENE-36. INTEGRATING TRANSCRIPTOMICS AND KINOMICS IDENTIFIES SYNERGISTIC DRUG COMBINATIONS FOR GLIOBLASTOMA TREATMENT
Authors: Anna Jermakowicz, Vasileios Stathias, Robert Suter, James Duncan, Stephan Schürer, Nagi Ayad
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) is the most common and malignant adult brain tumor. Despite years of research, few advancements have been made in its management. One promising avenue of research has been treatment with BRD4 inhibitors, which decrease oncogene expression in GBM cells. However, resistance to these inhibitors is rapidly acquired. Kinome reprogramming is thought to underlie this resistance, suggesting a need for combination therapy with kinase inhibitors. The goal of this study is to determine whether transcriptomic and kinomic profiling of GBM tumors will identify synergistic drug pairs for GBM treatment. We profiled the active kinome on a set of three newly-diagnosed GBM patient-derived xenograft (PDX) tumors and three recurrent tumors using quantitative SILAC mass spectrometry. Additionally, kinome reprogramming following BET inhibition was profiled in vitro using the BET inhibitor JQ1. Kinome activity was uploaded into our novel computational platform, SynergySeq, to assess the synergistic potential of kinase inhibitors with JQ1. Additionally, single cell RNA-sequencing of a GBM tumor was used to determine the cell populations affected by each inhibitor. To quantify synergy in response to combination therapy, cells were treated with a combination matrix of JQ1 and a kinase inhibitor in variable concentrations and cell death was quantified via ATP levels. Our results showed that newly-diagnosed tumors were predicted to be sensitive to combined BET inhibition with Bcr/Abl, EGFR, and FGFR kinase inhibitors. Recurrent tumors were sensitive to combined Bcr/Abl and FGFR inhibitors but were not sensitive to EGFR inhibitors. We screened inhibitors in vitro and found a synergistic effect for the combination of JQ1 and TAS120, a pan-FGFR inhibitor. These data suggest that clinically a brain penetrant BET inhibitor should be effective in combination with a brain penetrant FGFR inhibitor. Importantly, our computational platform is a novel informatics-based approach for targeted therapy in a patient-specific and disease-specific manner.
ATIM-12. AVELUMAB IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME-THE SEJ STUDY
Authors: Francois Jacques, Garth Nicholas, Ian Lorimer, Victorine Sikatifoko, Nathalie Dumais
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Glioblastoma Multiforme (GBM) has well documented systemic and local immunosuppressive mechanisms to escape immune surveillance. GBM tumor cells as well as the microglia within it have a high PD-L1 surface expression which may make it susceptible to anti-PD-L1 antagonism and ADCC with avelumab therapy. Combining immunotherapy to other chemotherapeutic agents have proven benefical in certain cancers. A clinical trial looking at adding avelumab to standard therapy in patients with newly diagnosed GBM is indicated. METHODS This is a single center, phase 2, open label study of avelumab 10 mg/kg Q2W for 156 weeks duration in patients receiving standard therapy for newly diagnosed GBM. Thirty patients will be entered into the study within 3 weeks of completing combined radiotherapy/temozolomide. Here we will report the results our second interim analysis when the first 20 patients will have completed 52 weeks or an end of study event which will occur in 10–2019. RESULTS The results will be presented at the meeting
Whole Exome Sequencing Reveals Multiple Driver Events in Chronic Lymphocytic Leukemia Patients with Acquired Ibrutinib Resistance
Authors: Chingiz Underbayev, Inhye E Ahn, Hailey Harris, Lauren T Vaughn, Mehdi Pirooznia, Liqiang Xi, Mark Raffeld, Sarah E. M. Herman, Adrian Wiestner
Journal: Blood (2019)
NHS is facing one its “bleakest” winters after worst ever performance on key targets
Authors: Gareth Iacobucci
Journal: BMJ (2019)

Doctors have been warned that the NHS faces a “bleak” winter, as the latest figures showed the worst ever performance on key targets on waiting times. In October only 83.6% of patients at all types of emergency department and just 74.5% in major A&E departments were seen within four hours, against the target of 95%, show the official figures from NHS England.1

This was the lowest level since the target was introduced in 2004 and amounts to a sixth of patients waiting more than four hours. The number of people waiting on trolleys because no beds were available …
Approaching Venous Thromboembolism Disease (DVT) from Another Perspective: Better Management in a Multidisciplinary DVT Unit Improves Clinical Outcomes and Post Thrombotic Syndrome. One-Year Experience in Our Hospital
Authors: Milagros Suito, Maria Cerdá, Olga Benítez, Alba Cabirta, Francesc Bosch, Amparo Santamaria
Journal: Blood (2019)
Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
Authors: Jorge M. Ramos Perez, Tapan M. Kadia, Guillermo Montalban-Bravo, Stefan Faderl, Koji Sasaki, Naval Daver, Courtney D. DiNardo, Lucia Masarova, Alessandra Ferrajoli, Elias Jabbour, Gautham Borthakur, Hind Al Azzawi, Naveen Pemmaraju, Marina Konopleva, Sherry A. Pierce, Guillermo Garcia-Manero, Michael Andreeff, Hagop M. Kantarjian, Farhad Ravandi, Yesid Alvarado
Journal: Blood (2020)
Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study
Authors: Pierluigi Porcu, Brad M. Haverkos, Onder Alpdogan, Marcelo Capra, Tatyana A. Feldman, Elizabeth Brem, Anusha Vallurupalli, Jonathan E. Brammer, Ana Schriefer, Juliana Pereira, Anil Tulpule, Stefan K. Barta, Locke J. Bryan, Richard Trauger, Sebastian Obrzut, John Gutheil, Afton Katkov, Robert McRae, Ivor Royston, Douglas V. Faller
Journal: Blood (2019)
Genome-Wide Histone Acetylation Profiling in Chronic Lymphocytic Leukemia Reveals a Distinctive Signature in Stereotyped Subset #8
Authors: Maria Tsagiopoulou, Vicente Chapaprieta, Nuria Russiñol, Fotis Psomopoulos, Nikos Papakonstantinou, Niki Stavroyianni, Achilles Anagnostopoulos, Panagoula Kollia, Elias Campo, Kostas Stamatopoulos, José I. Martin-Subero
Journal: Blood (2019)
1 vs 12 Months of Dual Antiplatelet Therapy for Patients After Percutaneous Coronary Intervention—Reply
Authors: Hirotoshi Watanabe, Takeshi Kimura
Journal: JAMA (2019)

In Reply In response to the 1-year primary analysis of the STOPDAPT-2 trial, Dr Tan commented on the appropriateness of the noninferiority margin and the actual timing of aspirin discontinuation in the 1-month DAPT group.1
Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies
Authors: John N. Allan, Krish Patel, Anthony R. Mato, William G. Wierda, Javier Pinilla Ibarz, Michael Y. Choi, Susan M. O'Brien, Jeff P. Sharman, Mazyar Shadman, Douglas E Gladstone, Matthew S. Davids, John M. Pagel, Renee Ward, Gary Acton, Pietro Taverna, Judith A. Fox, Richard R. Furman, Jennifer R. Brown
Journal: Blood (2019)
Metabolites in a mouse cancer model enhance venous thrombogenicity through the aryl hydrocarbon receptor–tissue factor axis
Authors: Mostafa Belghasem, Daniel Roth, Sean Richards, Marc Arthur Napolene, Joshua Walker, Wenqing Yin, Nkiruka Arinze, Chimera Lyle, Cheryl Spencer, Jean M. Francis, Cristal Thompson, Christopher Andry, Stephen A. Whelan, Norman Lee, Katya Ravid, Vipul C. Chitalia
Journal: Blood (2019)
Use of Ex Vivo Graft Manipulation and Posttransplant Cyclophosphamide Result in Low GvHD Rates and Acceptable Engraftment after RIC Regimens in Pediatric Mismatched SCT
Authors: Peter Lang, Michaela Döring, Anne-Marie Lang, Patrick Schlegel, Christian M. Seitz, Robin Fischer, Ursula Holzer, Ines Brecht, Rupert Handgretinger
Journal: Blood (2019)
RDNA-04. CIRCADIAN RHYTHMS AND RADIATION CHRONOTHERAPY IN GLIOBLASTOMA CELL LINES AND CENTRAL NERVOUS SYSTEM CELL CONTROLS
Authors: Dorela Shuboni-Mulligan, Madeline Dahut, Demarrius Young, Mark Gilbert, Terri Armstrong
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Chronotherapy is the optimally timed administration of treatment based on the circadian clock. In non-CNS cancers, circadian rhythms (CR) drive the expression of mechanisms responsible for radiation sensitivity and associated toxicity. Our previous work has shown that cranial irradiation in GBM patients produces a high incidence of hypersomnolence and susceptibility is linked to circadian clock gene polymorphisms. This study determined if CR can be demonstrated using in vitro GBM and CNS cells and then if sensitivity to radiation is circadian time and tissue dependent. METHODS Rat GBM, fibroblasts, and suprachiasmatic nucleus (SCN) cells were used and compared to human U251 GBM cells. Cells were synchronized using the serum shook method; protein levels for PER2 expression over 24 hr in 4 hr intervals were quantified to confirm CR. Colony formation and 3D invasion assays after radiation (0-8Gy or 8Gy, respectively) 8 and 20 hrs after synchronization were evaluated. RESULTS All cell types demonstrated CR by PER2 expression (trough ~8hr post (CT8); peak ~20hrs post (CT20)). In rat, GBM (LD50 = 4Gy) and SCN cells (LD50 =5 Gy) showed lower sensitivity than fibroblasts (LD50= 2 Gy). Human U251 GBM cells had similar radiation sensitivity to rat GBM. Time-of-day effects were dependent on tissue type with both rat and human GBM cell lines more affected by radiation at CT20, with less invasion (CT20:-35488.5±2622.1 vs CT8:-23160.5±3273.4µm) and survival in the colony assay (F(1,71)=4.105,p&lt; 0.05). Conversely, SCN cells which drive sleep-wake, showed the converse with greater effect at the 8hr compared with 20hr (F(1, 35)=19.93,p&lt; 0.001). CONCLUSIONS These data suggest that timing of radiation could be optimized to improve detrimental effects on healthy tissue, while still providing effective intra-tumor doses. In future studies, we will interrogate the mechanisms driving time-of-day effects in cells and test radiation chronotherapy in our radiation-induced hypersomnolence mouse model.
Circulating tumour associated cells in esophageal cancers are resistance educated per previous chemo treatments
Authors: S. Limaye, T. Crook, A. Ranade, D. Patil, D. Akolkar, V. Datta, S. Schuster, R. Page, C. Sims, R. Patil, A. Srinivasan, S. Khan, S. Patil, V. Mhase, S. Apurwa, R. Datar
Journal: Annals of Oncology (2019)
HOUT-14. PROGNOSTIC IMPACT OF FIRST PSEUDOPROGRESSION ON MRI IN GLIOBLASTOMA, AN 11 YEARS EXPERIENCE FROM A CANADIAN UNIVERSITY CENTER
Authors: Elie Zeidan, Anis Assad, Laurent Letourneau Guillon, Karl Belanger, Emilie Lemieux Blanchard, Bernard Lemieux, Jean-Paul Bahary, David Roberge, Laura G Masucci, Cynthia Menard, Carole Lambert, Robert Moumdjian, France Berthelet, Meriem Ben-Abdallah, Jacques De Guise, Marie Florescu
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND In glioblastomas (GBM) patients the first post-radiation MRI is usually difficult to interpret given the post-radiotherapy enhancement and possible pseudo-progression which is present in almost 50% of the patients. METHODS We retrospectively analyzed all patients with GBM treated between 2006 and 2017 at the CHUM (SARDO database). If the first brain MRI done within 3 months after the systemic treatment showed progression of contrast, these patients were considered pseudoprogressors (PsP) while the patients who had stable or response to treatment were the non-progressors (nP). If progression persisted in subsequent MRI with a change of treatment within 6 months, they were considered early progressors (eP). If subsequent MRI improved or was stable, they were classified as nP (or true pseudo-progression). RESULTS In our cohort of 470 patients with GBM, 57.7% were nP and 42.3% were PsP after the first post-treatment imagery. The median follow-up was 10 months. The nP had a longer mOS 15.3m vs 11.3m, p &lt; 0.001, regardless of subsequent evolution. After the second assessment, 67.8% of PsP patients were then considered as eP and 36.4% of nP patients also progressed within 6 months. The nP either after the first or second evaluation had the same mOS (19.9m vs 18.3m), just like the eP (9.3m vs 8.6m), independently of the subsequent treatment. No demographic, molecular or clinical factor predicted PsP, except for tumor size (&gt; 5cm, p=0.024). PsP incidence was similar between 2006–2011 (PsP 57.8%) and 2012–2017 (42.2%). The 1y OS with pseudo progression at the first MRI was 39.7% vs 54.8% with no progression (p=0.001) which has a meaningful impact for the patient. CONCLUSION Pseudo-progression is frequent (42%) in glioblastoma and predicts a poorer prognosis with 1y OS of 39,7%. In fact, PsP patients have more than two-thirds chance to progress precociously.
Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial
Authors: Preetesh Jain, Hun Ju Lee, Raphael Eric Steiner, F. B. Hagemeister, Felipe Samaniego, Jason R. Westin, Loretta J. Nastoupil, Sairah Ahmed, Swaminathan P. Iyer, Jorge Enrique Romaguera, Shuangtao Zhao, Krystle Nomie, Chi Young Ok, Rashmi Kanagal-Shamanna, Onyeka Oriabure, Guofang Xu, Liang Zhang, Changying Jiang, Dayoung Jung, Lucy Navsaria, Wendy Chen, Omar Moghrabi, Tayyaba Nizam, Chloe Marie McClain, Maria Badillo, Selvi Thirumurthi, David Santos, Guilin Tang, Keyur Patel, Sattva S Neelapu, Linghua Wang, Nathan H. Fowler, Michael L. Wang
Journal: Blood (2019)
SCIDOT-05. DEVELOPING VARIABLE LYMPHOCYTE RECEPTORS THAT TARGET PATHOLOGICALLY EXPOSED NEURAL ECM TO TREAT GLIOBLASTOMA
Authors: Benjamin J Umlauf, Paul A Clark, Jason M Lajoie, Julia V Georgieva, Samantha Bremner, Brantley R Herrin, Eric V Shusta, John S Kuo
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION The median survival of gliobastoma (GBM) patients remains less than two years despite aggressive treatments. Current targeted GBM therapies demonstrate initial therapeutic benefit; however, patients relapse due to therapeutic resistance and failure to eliminate GBM cells at the invasive margin. Therefore, we propose a two-prong approach: first, target pathologic disruption of the blood brain barrier (BBB) via exposure of neural ECM rather than disease markers to overcome therapy-resistant GBM; and second, designing therapeutic payloads that extracellularly spread throughout the tumor volume. METHODS Variable Lymphocyte Receptors (VLRs, a lamprey-derived antigen recognition system) were identified with high specificity for neural ECM. Candidate VLRs underwent further refinement using ex vivo tissue staining. Utilizing pathologic disruption of BBB as an approach for targeting GBM was confirmed in vivo with intracranial murine glioblastoma models. Finally, an immunogenic peptide was attached via a cleavable linker to the neural ECM binding VLRs for conditional release extracellularly to spread throughout the tumor. RESULTS The lead neural ECM-binding VLR candidate, named P1C10, demonstrates diffuse binding to parenchymal neural ECM, without detectable binding to other tissues. P1C10 demonstrates nanomolar affinity for neural ECM, and preferentially accumulates in intracranial GL261 and U87 murine GBM models. Finally, P1C10-targeted doxorubicin-loaded liposomes significant increased survival of mice with intracranial GBM. In additional studies, treating murine GBM models with a P1C10 VLR linked to an immunogenic peptide reduced GBM proliferation and increased infiltration of cytotoxic T cells. CONCLUSIONS We present proof-of-concept demonstration for targeting intracranial GBM via neural ECM exposed at pathological BBB disrupted sites. Additionally, P1C10 neural ECM-targeting VLR delivers chemotherapy-loaded nanoparticles and immunogenic peptides designed to spread extracellularly throughout the tumor. Thus, this novel strategy links a physiological ECM targeting scheme with extracellular-released therapeutics to treat primary GBM, and has potential for delivering therapies to other CNS diseases with pathological BBB.
In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors
Authors: Manuela Mancini, Cecilia Monaldi, Sara De Santis, Cristina Papayannidis, Michela Rondoni, Luana Bavaro, Margherita Martelli, Antonio Curti, Maria Chiara Fontana, Samantha Bruno, Roberta Zanotti, Massimiliano Bonifacio, Luigi Scaffidi, Livio Pagano, Marianna Criscuolo, Francesco Albano, Fabio Ciceri, Chiara Elena, Patrizia Tosi, Massimo Delledonne, Carla Avanzato, Luciano Xumerle, Peter Valent, Giovanni Martinelli, Michele Cavo, Simona Soverini
Journal: Blood (2019)
Under-utilisation of evidence-based treatment a partial explanation to the unfavourable prognosis in diabetic patients with acute myocardial infarction
Authors: A Norhammar, K Malmberg, L Ryden, P Tornvall, Ulf Stenestrand, L Wallentin
Journal: Circulation (2001)

Under-utilisation of evidence-based treatment a partial explanation to the unfavourable prognosis in diabetic patients with acute myocardial infarction
Effect of Unilateral Pulmonary Artery Obstruction on Circulatory Dynamics in Dogs with Chronic Atrial Septal Defects
Authors: DALMO DES. AMORIM, HIRAM W. MARSHALL, DAVID E. DONALD, EARL H. WOOD
Journal: Circulation Research (1961)

Determinations of pressure, blood flows, and calculated pulmonary vascular resistance were made prior to and during acute individual occlusion of the right and left main branches of the pulmonary artery in random sequence in eight anesthetized, closed-chest dogs witn chronic atrial septal defects. Similar observations were made with occlusion of only the left pulmonary artery in three additional dogs. Obstruction of the pulmonary artery to one lung was immediately followed by a rise in systolic pressure in the right ventricle and pulmonary artery proximal to the obstruction, from an average normal value of 33.1 mm. Hg to an average value of 40.9 mm. Hg (range 32 to 47). This change was not associated with demonstrable systematic effects on right atrial or systemic arterial pressure or on the systemic blood flow. As would be expected, the average calculated ratio of pressure to flow (vascular resistance) across the unoccluded lung was elevated during the obstruction. The resistance value during the occlusion, however, was less than the estimated pressure/flow ratio for this same lung, based on the measurements made prior to the occlusion. This apparent effective decrease in vascular resistance of the unoccluded lung is probably related to dilation of the pulmonary vessels as a result of an increase in intravascular pressure caused by the sudden removal of approximately half of the pulmonary vasculature from the circulation. In spite of the elevation in right ventricular systolic pressure, occlusion of the left pulmonary artery was associated with a slight increase in pulmonary blood flow and a definite increase in the magnitude of the left-to-right shunt across the atrial septal defect, whereas no systematic effects were obtained during obstruction of the right branch in association with the same approximate levels of right ventricular systolic pressure. These data are regarded as further evidence that the preferential shunting of blood from the right lung in the presence of an atrial septal defect of the secundum type is primarily due to the anatomical relation between the opening of these vessels into the left atrium and the position of the defect in the atrial septum. Furthermore, they emphasize the importance of dynamic factors, related to the manner, site, and direction in which the pulmonary venous blood drains into the left atrium, as important determinants of the left-to-right shunt via such defects.
Non-immunogenic, low-toxicity and effective glioma targeting MTI-31 liposomes
Authors: Xiaoyi Wang, Nana Meng, Songli Wang, Yanyu Zhang, Linwei Lu, Ruifeng Wang, Huitong Ruan, Kuan Jiang, Huan Wang, Danni Ran, Changyou Zhan, Ker Yu, Diane J. Burgess, Weiyue Lu
Journal: Journal of Controlled Release (2019)
CMET-02. ESTABLISHING THE SAFETY AND EFFICACY OF A NEW MULTI-AGENT INTRATHECAL TREATMENT PROTOCOL FOR PATIENTS WITH NEOPLASTIC MENINGITIS
Authors: Samer Zammar, Richard Eby, Brad Zacharia, Roy Strowd, Stuart Grossman, Dawit Aregawi, Glantz Michael
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND The prognosis for neoplastic meningitis (NM) remains dismal and single-agent (rather than multi-agent) chemotherapy remains the standard of care. Objective: To analyze survival of patients with NM receiving multi-agent vs. single-agent intrathecal chemotherapy and evaluate the safety of antitumor intrathecal biological agents. METHODS We compared a standardized multi-agent intrathecal treatment cohort to the corresponding patient level data acquired from 6 of the 7 randomized controlled trials (RCTs) conducted in patients with NM, all of which used single-agent intraventricular therapies. The toxicity of intrathecal biological agents was studied by analyzing the outcome data form patients with NM treated with at least 1 intrathecal biological drug. RESULTS 283 patients receiving multi-agent therapy were compared to 290 patients from the RCTs. Patients and tumor characteristics did not differ between groups. All patients from the multi-agent patient group were included in an intent-to-treat model. For all solid tumors, median survival (multi-agent vs. single-agent treatment) was 211 vs. 97 days, hazard ratio (HR) 3.39, p&lt; 0.001. For lymphoma, survival was 304 vs. 81 days, HR 2.10, p&lt; 0.001. Stratified by tumor histology, median survival for breast cancer NM was 315 days [95% CI 248–449], for lung cancer 193 days [127- 200]; for melanoma 307 days [65–1492], and for primary brain tumors 253 days [187- 348]. No additional toxicity was seen in the multi-agent compared to the single-agent treatment groups. In 110 patients, grade III toxicity occurred in 5.3%, 3.1%, 0% and 0% of patients receiving rituximab, trastuzumab, panitumumab, and alpha interferon. No difference in survival was seen when comparing patients with and without treatment related toxicity in any histological groups. CONCLUSION Multi-agent intraventricular chemotherapy was associated with dramatically increased survival in patients with solid tumor and lymphomatous NM. Incorporating biologic agents as part of a multi-agent intrathecal treatment regimen is very safe.
Safety and Efficacy of First Line Venetoclax Combinations in AML Patients Ineligible for Intensive Therapy, a Real World Data
Authors: Arie Apel, Yishay Ofran, Avraham Frisch, Yakir Moshe, Ofir Wolach, Chiya Leibovitch, Natalia Kreiniz, Maya Koren-Michowitz
Journal: Blood (2019)
Overall Survival of Glasdegib in Combination with Low-Dose Cytarabine and Azacitidine By Bone Marrow Blasts Among Adult Patients with Previously Untreated Acute Myeloid Leukemia: Comparative Effectiveness Using Indirect Treatment Comparisons
Authors: Sophie Van Beekhuizen, Timothy J Bell, Ana Gezin, Joseph C Cappelleri, Bart Heeg, Carl Selya-Hammer, Majed Charaan, Geoffrey Chan
Journal: Blood (2019)
Phenotypes of responders to mandibular advancement device therapy in obstructive sleep apnea patients: A systematic review and meta-analysis
Authors: Hui Chen, Danny J. Eckert, Paul F. van der Stelt, Jing Guo, Shaohua Ge, Elham Emami, Fernanda R. Almeida, Nelly T. Huynh
Journal: Sleep Medicine Reviews (2019)
Comparison of Outcomes between HSCT Donor Sources for Pediatric Patients with Hematologic Malignancies
Authors: Lauren Longo, Filippo Milano, Colleen Delaney, Marie Bleakley, Lauri S Burroughs, Brandon Hadland, Elisabetta Xue, Laura Roberts, Soheil Meshinchi, Kanwaldeep K. Mallhi, Monica Thakar, K Scott Baker, Corinne Summers, Ann Dahlberg
Journal: Blood (2019)